The better-than-expected Citigroup earnings and the best monthly retail sales jump since September 2012 provided a positive one-two punch for Wall Street.
The earnings beat helped offset some of the negativity from last week, when J.P. Morgan Chase's profit came in far below forecasts. Citigroup's results also offset some of the gloom ahead of what is expected to be a challenging quarter for corporate profits.
The 1.1% jump in retail sales in March also raised hopes that the spring thaw will coincide with a re-acceleration of economic growth after a lousy first quarter due to harsh winter weather.
Hot Chemical Companies To Own In Right Now: Hewlett-Packard Company(HPQ)
Hewlett-Packard Company and its subsidiaries provide products, technologies, software, solutions, and services to individual consumers and small- and medium-sized businesses (SMBs), as well as to the government, health, and education sectors worldwide. Its Personal Systems Group segment offers commercial personal computers (PCs), consumer PCs, workstations, calculators and other related accessories, and software and services for the commercial and consumer markets. The company?s Services segment provides consulting, outsourcing, and technology services to infrastructure, applications, and business process domains. Its Imaging and Printing Group segment provides consumer and commercial printer hardware, supplies, media, and scanning devices, such as inkjet and Web solutions, laser jet and enterprise solutions, managed enterprise solutions, graphics solutions, and printer supplies. The company?s Enterprise Servers, Storage, and Networking segment offers industry standard s ervers, business critical systems, storage platforms, and networking products, including switches, routers, wireless LAN, and TippingPoint network security products. Its HP Software segment provides enterprise IT management software, information management solutions, and security intelligence/risk management solutions. The company?s HP Financial Services segment offers leasing, financing, utility programs, and asset recovery services; and financial asset management services for enterprise customers, as well as specialized financial services to SMBs, and educational and governmental entities. Hewlett-Packard Company also provides business intelligence solutions that enable businesses to standardize on consistent data management schemes, connect and share data across the enterprise, and apply analytics, as well as licenses its specific technology to third parties. The company was founded in 1939 and is headquartered in Palo Alto, California.
Advisors' Opinion:- [By Matt Thalman]
In the following video, Fool contributor Matt Thalman points out one big reason why he believes opening a new position in Hewlett-Packard (NYSE: HPQ ) is not worth the risk today. While Matt feels that Meg Whitman has, up to this point, performed wonderfully in pulling the struggling technology company back from the edge of the cliff, the turnaround strategy still has a number of hurdles to overcome, and too many things still have to go according to plan.�
- [By Ben Levisohn]
The big question now: What impact will the closure happen to the fund’s biggest stock holding? As an activist investor, Relational doesn’t take many small positions. It holds 1.5% of Hewlett-Packard (HPQ) shares, for instance, 15% of SPX Corp. (SPW), 3.5% of B/E Aerospace (BEAV) and 4.6% of Timken (TKR).
5 Best Tech Stocks To Buy For 2014: Rexahn Pharmaceuticals Inc (RNN)
Rexahn Pharmaceuticals, Inc. (Rexahn) is a development-stage biopharmaceutical company. The Company focuses on the development of cures for cancer to patients worldwide. The Company�� pipeline features one drug candidate in Phase II clinical trials. The Company also has several other drug candidates in pre-clinical development. In addition, the Company has two renal cell carcinoma (CNS) candidates, Serdaxin, CNS Disorders drug for depression and neurodegenerative diseases and Zoraxel, which is a erectile dysfunction (ED) and sexual dysfunction drug that are in clinical stages and the Company is are exploring options for further development . The Company�� drug candidate, Archexin is an anticancer Akt inhibitor.
Archexin
Archexin is potent inhibitor of the Akt protein kinase (Akt) in cancer cells. Archexin has FDA orphan drug designations for five cancers (RCC, glioblastoma, and cancers of the ovary, stomach and pancreas). Multiple indications for other solid tumors can also be pursued. Archexin inhibit both activated and inactivated forms of Akt, and to reverse the drug resistance observed with the protein kinase inhibitors. Archexin is an antisense oligonucleotide (ASO) compound that is complementary to Akt mRNA, and selective for inhibiting mRNA expression and production of Akt protein. As of December 31, 2011, Archexin was in Phase II clinical trials for the treatment of pancreatic cancer with enrollment completed in September, 2011.
Serdaxin
Serdaxin is an extended release formulation of clavulanic acid, which is an ingredient present in antibiotics approved by the FDA. The Company had been developing Serdaxin for the treatment of depression and neurodegenerative disorders. From January to September, 2011, the Company conducted a randomized, double-blind, placebo-controlled study compared two doses of Serdaxin, 0.5 milligram and 5 milligram, to placebo over an eight-week treatment period for major depressive disorder (MDD) patients. As of Dec! ember 31, 2011, the Company had not made a determination of Serdaxin�� future paths or resource allocations to further develop Serdaxin to treat MDD.
Zoraxel
Zoraxel is an orally administered, on-demand tablet to treat sexual dysfunction. Zoraxel is a dual enhancer of neurotransmitters in the brain that play a key role in sexual activity phases of motivation and arousal, erection and release, and may be the ED drug to affect all three of these phases of sexual activity. As of December 31, 2011, the Company was evaluating how to proceed with the Phase IIb study of Zoraxel.
The Company�� Pre-clinical Pipeline Drug Candidates includes RX-1792, which is a small molecule anticancer EGFR inhibitor; RX-5902, which is a small molecule anticancer ribonucleic acid (RNA) helicase regulator; RX-3117, which is a Small molecule anticancer deoxyribonucleic acid (DNA) synthesis Inhibitor; RX-8243, which is a small molecule anticancer aurora kinase inhibitor; RX-0201-Nano, which is a nanoliposomal anticancer Akt inhibitor; RX-0047-Nano, which is an nanoliposomal anticancer HIF-1 alpha inhibitor and RX-21101, which is a nano-polymer Anticancer.
Advisors' Opinion:- [By James E. Brumley]
With just a quick glance at a chart of Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), it would be easy to conclude it's nothing but a volatile mess. When you take a step back and look at a long-term weekly chart of RNN, however, it starts to become clear that this small cap biopharma name is on the verge of a monster-sized breakout. First things first, however.
- [By Roberto Pedone]
One under-$10 biopharmaceutical player that's just starting to move into breakout territory is Rexahn Pharmaceuticals (RNN), which is engaged in the development of novel treatments for cancer to patients. This stock has been on fire so far in 2013, with shares up sharply by 62%.
If you take a look at the chart for Rexahn Pharmaceuticals, you'll notice that this stock has been uptrending strong for the last month, with shares moving higher from its low of 36 cents per share to its intraday high of 53 cents per share. During that uptrend, shares of RNN have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of RNN into breakout territory above some near-term overhead resistance levels at 49 cents to 50 cents per share. It's worth noting that volume today is tracking in extremely strong with over 3 million shares traded, versus its three-month average action of 1.22 million shares.
Traders should now look for long-biased trades in RNN if it manages to break out above Thursday's intraday high of 53 cents per share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 1.22 million shares. If that breakout hits soon, then RNN will set up to re-test or possibly take out its next major overhead resistance levels at 64 cents to its 52-week high at 66 cents per share. Any high-volume move above 66 cents to 67 cents per share could then send RNN towards its next major overhead resistance levels at 81 cents per share.
Traders can look to buy RNN off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day moving average at 47 cents per share. One can also buy RNN off strength once it clears 53 cents per share with volume and then simply use a stop that sits a comfortable percentage from your entry point.
5 Best Tech Stocks To Buy For 2014: Nortech Systems Incorporated(NSYS)
Nortech Systems Incorporated operates as a contract manufacturing company. It manufactures wire harness cable and printed circuit board assemblies, electronic sub-assemblies, higher level assemblies, and complete devices. The company also provides value added services and technical support, including design, testing, prototyping, and supply chain management; and repair services on circuit boards used in machines in the medical industry. In addition, it engages in the design, manufacture, and post-production service of electronic and electromechanical medical devices for diagnostic, analytical, and other life-science applications. Nortech Systems Incorporated serves various industries that include aerospace and defense; medical; and the industrial markets, which include industrial equipment, transportation, vision, agriculture, and oil and gas. The company markets its products through sales force and independent manufacturers? representatives. Nortech Systems Incorporated was founded in 1981 and is headquartered in Wayzata, Minnesota.
Advisors' Opinion:- [By James E. Brumley]
In a perfect world stocks would move in predictable, manageable ways. We don't live - nor do we trade in - a perfect world. In the real world we have to adapt to and deal with the curve balls the market throws us, and there are no two stocks that illustrate that point better than Document Security Systems, Inc. (NYSEMKT:DSS) and Nortech Systems Incorporated (NASDAQ:NSYS) to today. While both NSYS and DSS are up today, one's overbought and ripe for a pullback, while the other is likely at the beginning of a trade-worthy rally.
5 Best Tech Stocks To Buy For 2014: F5 Networks Inc.(FFIV)
F5 Networks, Inc. provides application delivery networking technology that optimizes the delivery of network-based applications, and the security, performance, and availability of servers, data storage devices, and other network resources in the Americas, EMEA, Japan, and the Asia Pacific. The company offers BIG-IP, an application delivery controller; VIPRION, a chassis-based application delivery controller; and FirePass, an appliance that provides SSL VPN access for remote users of Internet protocol networks, and applications connected to the networks from Web browser on any device. It also offers Application Security Manager, an application firewall; WebAccelerator that speeds Web transactions by optimizing individual network object requests, connections, and end-to-end transactions from browser to databases; WAN Optimization Manager, which integrates application delivery with WAN optimization technologies; Access Policy Manager that provides secure, granular, and contex t-aware control of access to applications; Edge Gateway, a remote access product, which offers context-aware, policy controlled, and remote access to applications at LAN speed; Enterprise Manager that allows customers to discover and view company?s products in a single window; and ARX product family, a series of high performance and enterprise-class intelligent file virtualization devices. In addition, F5 Networks provides Data Manager, a software product, which interfaces with file storage devices; iControl, an application programming interface that allows customers to control their products in the network; iRules, a programming language embedded in TMOS architecture; and consulting, training, maintenance, and other technical support services. The company sells its products to enterprise customers and service providers through various channels, including distributors, value-added resellers, and systems integrators. F5 Networks, Inc. was founded in 1996 and is headquartered in Seattle, Washington.
Advisors' Opinion:- [By Lee Jackson]
F5 Networks Inc. (NASDAQ: FFIV) has been all over the board in the past year, trading in an almost 45 point range. Analysts around Wall Street in addition to Deutsche Bank are very positive on core growth accelerating in the second half of 2013 as data center orders build. Deutsche Bank has a $100 price objective, and the consensus target is $96.
- [By shash63] evenue of $420.0 million, up 3 percent from $406.5 million in the prior quarter and 20 percent from $350.2 million in the second quarter of fiscal 2013. Moreover, revenues were positively impacted by an 18.0% hike in Services revenues and a 21.6% increase in Product revenues on a year-over-year basis.
Application Delivery Controller, or ADC, segment accounts for the product revenue of the Company. Product revenue of $225.1 million grew 3% sequentially and 22% year-over-year, representing 54% of total revenue.. With improvisation in data centers, it announced an updated version of its chief ADC platform software, BIG-IP.
The updated version of BIG-IP, called BIG-IP v11.4, simplifies management of applications and data over physical networks, virtual networks, and cloud environment. This updated software will enhance its ADC segment. Furthermore, Cisco�� exit from the ADC market will add to F5 Networks��market share growth opportunity. Its market share is expected to improve from 27.1% currently to 27.6% by the end of fiscal year 2015.
The increasing usage of 3G and 4G data from mobile devices is increasing the demand for content and applications. This situation is increasing network complexity and reducing security, increasing the probability of cyber attacks. The security products S/Gi firewall, offered by the company, is certain to benefit from this market of cyber security. This product protects the network service providers' infrastructure to ensure network availability and performance.
It will also protect subscribers from threat during data sharing. S/Gi will enhance connections per second by 20 times, which is equivalent to 8 million people using a service providers' network. This product will also contribute to F5 Networks��total revenue as the cyber security markets rises due to increased data traffic.
Data centers are becoming the foundation of every organization, and I.T. departments are moving towards cloud storage
- [By John Moore]
Hackers, phrackers, and crackers continuously find loopholes, gaps, and other open doors into our data. No matter how complex the information security or how strong the firewall, threats will persist -- and sometimes circumvent even the best-designed security technologies. The general public's new realization of just how serious cyber threats are has put cybersecurity firms in the spotlight. Barracuda Networks (NYSE: CUDA ) , F5 Networks (NASDAQ: FFIV ) , and Check Point Software Technologies (NASDAQ: CHKP ) are three cybersecurity firms to watch in 2014.
- [By Monica Gerson]
F5 Networks (NASDAQ: FFIV) is estimated to post its Q4 earnings at $1.19 per share on revenue of $384.61 million.
US Airways Group (NYSE: LCC) is expected to report its Q3 earnings at $1.12 per share on revenue of $3.84 billion.
No comments:
Post a Comment